top of page
youtube cover2.png

PUBLICATIONS


Masoumeh Dorrani, Jifang Zhao,Nihel Bekhti, Alessia Trimigno, Sangil Min, Jongwon Ha, Ahram Han, Elizabeth O’Day, Jurre J. Kamphorst. Olaris Global Panel (OGP): A Highly Accurate and Reproducible Triple Quadrupole Mass Spectrometry-Based Metabolomics Method for Clinical Biomarker Discovery. Metabolites 2024 14(5), 280; https://doi.org/10.3390/metabo14050280

Alessia Trimigno, Nicole R. Holderman, Chen Dong, Kari D. Boardman, Jifang Zhao, Elizabeth M. O'Day. NMR Precision Metabolomics: Dynamic Peak Sum Thresholding and Navigators for Highly Standardized and Reproducible Metabolite Profiling of Clinical Urine Samples. Metabolites 2024, 14(5), 275; https://doi.org/10.3390/metabo14050275.

Elizabeth O'Day. NMR-Based Metabolite Clinical Diagnostics. [invited presentation, presented July 17, 2023 at Metabolomics Society 2023.]

Chandrashekhar Honrao, Masoumeh Dorrani, Jifang Zhao, Chen Dong, Alessia Trimigno, Keri B. Sheehan, Elizabeth O’Day, Jurre J. Kamphorst. Highly standardized metabolomic analysis of clinical samples using triple quadruple mass spectrometry. [poster presentation, presented June 5, 2023 at American Society for Mass Spectrometry meeting.] 

Alessia Trimigno, Jifang Zhao, William A. Michaud, Dane C. Paneitz, Chijioke Chukwudi, Keri B. Sheehan, Elizabeth M. O’Day, Seyed Alireza Rabi, Asishana Osho. Metabolic Reprogramming During DCD Heart Perfusion. [poster presentation, presented June 5, 2023 at American Transplant Congress.]

Alessia Trimigno, Chen Dong, Jifang Zhao, Chandrashekar Honrao, Keri B. Sheehan, and Elizabeth O’Day. New Tools For NMR-Metabolite Biomarker Discovery: Navigators, NUS and Signal Enhancement. [oral presentation, presented March 13, 2023 at PANIC NMR.]

 

Elizabeth O'Day. Multidimensional NUS NMR-based metabolomics for in vitro diagnostic discovery​. [invited presentation, presented August 31, 2022 at SMASH NMR.]

Chen Dong, Srihari Raghavendra Rao, Chandrashekhar Honrao, Leonardo O Rodrigues, Elizabeth M O'Day, Dirk R Kuypers. Non-Invasive Metabolite-Based Urine Signature Detects Over-Immunosuppression in Renal Transplant Recipients [poster presentation, presented June 6, 2022]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/non-invasive-metabolite-based-urine-signature-detects-over-immunosuppression-in-renal-transplant-recipients/.

Srihari Raghavendra Rao, Chandrashekhar Honrao, Keri Sheehan, Leonardo ORodrigues, Chen Dong, Elizabeth O’Day, and Dirk R. Kuypers. Non-Invasive Metabolite-Based Urine Signature Detects Over-Immunosuppression in Renal Transplant Recipients. [abstract/moderated poster presentation]. Proceedings of the International Transplant Science (ITS) 2022 Meeting; 2022 May. 

Chandrashekhar Honrao, Cristina Guarducci, Agostina Nardone, Wen Ma, Srihari Raghavendra Rao, Keri Sheehan, Chen Dong, Leo Rodrigues, Rinath Jeselsohn, Elizabeth O'Day. Isotopic Tracing Reveals Distinct Metabolic Changes with Palbociclib or Abemaciclib Treatment and Resistance in Breast Cancer Cell Lines [abstract/virtual poster presentation]. Proceedings of the 113th Annual Meeting of the American Association for Cancer Research (AACR); 2022 Apr. https://www.abstractsonline.com/pp8/#!/10517/presentation/17843 ​

Chen Dong, Chandrashekar Honrao, Leonardo O. Rodrigues, Josephine Wolf, Keri B. Sheehan, Matthew Surface, Roy N. Alacay, Elizabeth M. O'Day. Plasma Metabolite Signature Classifies Male LRRK2 Parkinson’s Disease Patients. Metabolites 12, 149 (2022). https://doi.org/10.3390/metabo12020149 

Dong C, Thomas S, Honrao C, Rodrigues LO, Tessier N, Zhang B, Sanati S, Vij KJ, Ernst BJ, Anderson KS, Opyrchal M, Ademuyiwa F, Peterson LL, Goetz MP, Northfelt D, O’Day E, Ma C. Identifying Metabolic Biomarkers of Response in Early-Stage Breast Cancer Patients. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; San Antonio (TX). SABC, 2021 Dec.  Olaris, Waltham, MA; Washington University in St. Louis, St. Louis, MO; Cedars-Sinai, Los Angeles, CA; Mayo Clinic, Phoenix, AZ; Mayo Clinic, Rochester, MN.  Program P5-13-20. https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Program%20Book.pdf?ver=2021-12-06-144030-433

Chandrashekhar Honrao, Nathalie Teissier, Bo Zhang, Robert Powers, and Elizabeth M. O’Day. Gadolinium-based Paramagnetic Relaxation Enhancement Agent Enhances Sensitivity for NUS Multidimensional NMR-based Metabolomics. Molecules, 26(17), 5115; (2021) .https://doi.org/10.3390/molecules26175115 

 

Chandrashekhar Honrao, Srihari Raghavendra Rao, Nathalie Teissier, S. Greg Call, Elizabeth M. O’Day, Filip Janku. Plasma-based metabolic profiling in metastatic gastrointestinal stromal tumors (GIST) [abstract]. In: Proceedings of the 112th Annual Meeting of the American Association for Cancer Research; 2021 April 10-15; Virtual. Olaris, Inc., Waltham (MA), MD Anderson Cancer Center, Houston (TX): AACR, 2021. Abstract nr LB031. https://www.abstractsonline.com/pp8/#!/9325/presentation/4540https://drive.google.com/file/d/1oFMW3kO1MyVvlfoVU5r6VmwIwdYF3LQj/view  

 

Hoyt, L. & O’Day, E. M. Perspective: A potential role for NUS in metabolite-based in vitro diagnostics. Magnetic Resonance in Chemistry 59, 257–263 (2021). https://doi.org/10.1002/mrc.5104  

 

O’Day, E. M., Idos, G. E., Hill, C., Chen, J. W. & Wagner, G. Cytidine monophosphate N-acetylneuraminic acid synthetase enhances invasion of human triple-negative breast cancer cells. OTT 11, 6827–6838 (2018). https://doi.org/10.2147/OTT.S177639  

 

O’Day, E.M., K. Leitzel, A. Lipton, et al. Pretreatment serum metabolome predicts PFS in first-line trastuzumab-treated metastatic breast cancer [poster]. In: Proceedings of the 2020 San Antonio Breast Cancer Symposium; San Antonio (TX). Olaris, Inc., Waltham (MA), Penn State Hershey Medical Center, Hershey (PA): SABC, 2020. P4-10-35 

https://www.sabcs.org/Portals/SABCS2016/2020%20SABCS/ALL%20ABSTRACTS%202-9.pdf?ver=2020-12-09-104626-337 

https://04546313-eae5-4287-890e-29465e7a9a22.filesusr.com/ugd/65dee3_9469b9523e274f5cab4376373951a3c6.pdf 

 

Wolf, Josephine, Chen Dong, Elizabeth M. O'Day. Metabolite Biomarkers of Response (BoRs) Towards a Fingerprint for the Evolution of Metastatic Breast Cancer. Progress in Biophysics and Molecular Biology,(2021). https://doi.org/10.1016/j.pbiomolbio.2021.08.005  

 

Zhang, B., Powers, R. & O’Day, E. M. Evaluation of Non-Uniform Sampling 2D 1H–13C HSQC Spectra for Semi-Quantitative Metabolomics. Metabolites 10, 203 (2020). https://doi.org/10.3390/metabo10050203  

Zhang, B., Warner, J., Pinto, C., Juric, D. & O'Day, E. NMR-metabolite-resonance signature to predict HR+ breast cancer patient response to CDK4/6 inhibitors. Journal of Clinical Oncology 37, 3043–3043 (2019). https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.3043 

Zhang, B., Powers, R. & O’Day, E.M. Evaluation of Non-Uniform Sampling 2D 1H–13C HSQC Spectra for Semi-Quantitative Metabolomics [poster]: in Experimental Nuclear Magnetic Resonance Conference; 2020. Olaris, Inc, Waltham (MA),  University of Nebraska-Lincoln, Lincoln (NE): ENC, 2020. https://04546313-eae5-4287-890e-29465e7a9a22.filesusr.com/ugd/65dee3_8134fff2fd644ebe974c17e4de732a6e.pdf  

bottom of page